Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Visx' Star is approvable for PRK, contingent on submission of additional data -- panel.

This article was originally published in The Gray Sheet

Executive Summary

VISX' STAR PRK APPROVABLE RECOMMENDATION CONTINGENT ON ADDITIONAL DATA submission to FDA as well as postmarket studies. The ophthalmic excimer laser should be approved by FDA for treating nearsightedness with photorefractive keratectomy if the requirements are met, the agency's Ophthalmic Devices Panel recommended in a 7-1 vote at an Oct. 20 meeting in Gaithersburg, Maryland.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel